Visualizing every day of the US stock market for the last 10 years

CoreWeave is soaring as Microsoft’s $17.4 billion deal with Nebius shows the immense value and continued demand for all parts of the AI data center ecosystem.

One additional reason for CoreWeave’s jump may be that its pending acquisition of AI data center infrastructure company Core Scientific looks like a great deal compared to Microsoft’s renting of (more broad and advanced) AI data center capacity from Nebius.

CoreWeave’s all-stock deal to buy Core Scientific was initially valued at ~$9 billion, but with the subsequent decline in its shares, it’s worth about 40% less. And in purchasing Core Scientific, CoreWeave is saving $10 billion in what it would have paid the company to lease data center infrastructure over the next 12 years.

As it stands, Microsoft is getting about 300 megawatts in data center power capacity from Nebius, while Core Scientific boasts that its footprint is in excess of 1,300 megawatts. So, on the surface, it looks like an absolute steal for CoreWeave.

But again, this is not an apples-to-apples comparison; not all access to AI computing infrastructure is created equal.

There are differences in the type of AI infrastructure provided by the two: Nebius owns GPUs, while Core Scientific doesn’t, and what it provides in the software layer isn’t offered by Core Scientific as a stand-alone entity. This is the difference between the “full stack” approach (Nebius) and a “colocation” approach (Core Scientific).

That being said, CoreWeave’s acquisition of Core Scientific, once completed, will make the combined entity’s business model look more like Nebius’ model, which, as Microsoft just told us, is something that top hyperscalers are willing to pay a pretty penny for.

UnitedHealth rose more than 4% in premarket trading on Tuesday after the company disclosed that it expects the majority of its Medicare Advantage enrollees will be on plans rated four stars or higher in 2026.

Though the data is only preliminary, about 78% of UNH’s Medicare Advantage members are in plans rated four stars or higher, the company said in a regulatory filing Tuesday morning. On Monday, the company said it plans to reiterate its full-year guidance when it meets with investors this week.

Insurance companies that provide government-sponsored plans, like Medicare Advantage, have struggled this year amid unexpected rising costs. Plans that are rated four stars or higher earn bonus payments and are typically more lucrative for healthcare insurance providers.